PUBLISHER: TechSci Research | PRODUCT CODE: 1668178
PUBLISHER: TechSci Research | PRODUCT CODE: 1668178
Malignant Mesothelioma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By End User, By Region and Competition, 2020-2030F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
Global Malignant Mesothelioma Therapeutics Market was valued at USD 245.65 Million in 2024 and is expected to reach USD 360.11 Million by 2030 with a CAGR of 6.54% during the forecast period. Malignant mesothelioma is a rare and aggressive form of cancer that affects the mesothelial cells lining the chest, abdomen, and heart. This disease is primarily associated with asbestos exposure, and its prognosis is often bleak. However, recent advancements in the field of oncology and the pharmaceutical industry have given rise to a growing market for malignant mesothelioma therapeutics. While malignant mesothelioma remains relatively rare, its incidence has been increasing globally. This is partly due to delayed diagnoses and the long latency period associated with asbestos exposure. Improved diagnostic techniques, including biomarker identification and imaging technologies, have enabled earlier detection of mesothelioma. Early diagnosis is critical for effective treatment. The pharmaceutical industry has witnessed the development of novel therapies and treatment approaches for malignant mesothelioma. These include immunotherapy, targeted therapy, and gene therapy, which offer hope for better outcomes. Governments in many countries have introduced regulations to restrict asbestos use, which can potentially reduce future cases of mesothelioma. Additionally, healthcare reforms aim to improve access to treatment for affected individuals. The global malignant mesothelioma therapeutics market is witnessing significant growth, driven by advancements in diagnosis and treatment options. Patients diagnosed with this aggressive cancer now have more hope than ever before, thanks to innovative therapies and a growing body of research. While challenges still exist, the dedication of pharmaceutical companies, research institutions, and advocacy groups promises a brighter future for those affected by malignant mesothelioma.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 245.65 Million |
| Market Size 2030 | USD 360.11 Million |
| CAGR 2025-2030 | 6.54% |
| Fastest Growing Segment | Pemetrexed |
| Largest Market | North America |
Key Market Drivers
Increasing Incidence Rates of Malignant Mesothelioma
Malignant mesothelioma, a rare and aggressive cancer primarily associated with asbestos exposure, has been on the rise globally in recent years. This alarming increase in incidence rates has spurred significant research and development efforts in the field of mesothelioma therapeutics. As more individuals are diagnosed with this devastating disease, the demand for effective treatment options is growing, driving the global malignant mesothelioma therapeutics market forward. According to
Key Market Challenges
Limited Awareness and Early Diagnosis
One of the most significant hurdles in managing malignant mesothelioma is the widespread lack of awareness about the disease, both among the general public and healthcare professionals. Mesothelioma is a rare and aggressive form of cancer, often linked to asbestos exposure, but its symptoms are vague and non-specific, such as chest pain, shortness of breath, and fatigue. These overlapping symptoms are commonly associated with other, more prevalent conditions, which can cause delays in diagnosis. Unfortunately, this leads to diagnoses at later, more advanced stages of the disease, making effective treatment much more difficult. Early detection is key to improving prognosis, but without routine screening methods, identifying mesothelioma at an earlier stage remains a challenge. In addition, because healthcare providers may not regularly suspect mesothelioma in patients with such symptoms, the disease is often misdiagnosed or overlooked until it is too late. Public awareness campaigns, as well as ongoing education for healthcare professionals, are crucial to improving early detection rates and providing patients with better treatment outcomes.
Key Market Trends
Increasing Focus on Immunotherapies and Targeted Therapies
The increasing focus on immunotherapies and targeted therapies is rapidly transforming the Global Malignant Mesothelioma Therapeutics Market. Traditional treatments for mesothelioma, including chemotherapy and radiation, have proven limited in their effectiveness due to the aggressive nature of the disease and its resistance to conventional treatment approaches. In recent years, however, there has been a paradigm shift toward developing more advanced, targeted therapies and immunotherapies that leverage the body's immune system to fight cancer more effectively. In March 2023, Merck, in collaboration with the Canadian Cancer Trials Group (CCTG), has reported that their Phase 2/3 trial, known as CCTG IND.227/KEYNOTE-483, assessing the effectiveness of KEYTRUDA, Merck's anti-PD-1 therapy, combined with chemotherapy, has successfully achieved its primary goal of improving overall survival (OS) in the initial treatment of individuals diagnosed with unresectable advanced or metastatic malignant pleural mesothelioma.
Immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, are showing great promise in mesothelioma treatment. These therapies work by enhancing the body's immune response to tumor cells or by directly targeting the cancerous cells themselves. The success of immunotherapies in other cancers, such as melanoma and non-small cell lung cancer, has sparked increased interest in their application for mesothelioma. Research into the use of immune checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), in combination with traditional treatments has shown encouraging results, leading to clinical trials and ongoing investigations into their potential.
Key Market Players
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Merck & Co. Inc.
- Pfizer Inc.
- Eli Lilly and Co.
- Sanofi S.A.
- AstraZeneca Plc
- Bayer AG
- Regeneron Pharmaceuticals Inc.
- GSK Plc
Report Scope:
In this report, the Global Malignant Mesothelioma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Malignant Mesothelioma Therapeutics Market, By Drug Type:
- Pemetrexed
- Cisplatin
- Carboplatin
- Gemcitabine
- Vinorelbine
- Others
Malignant Mesothelioma Therapeutics Market, By Route of Administration:
- Oral
- Parenteral
Malignant Mesothelioma Therapeutics Market, By End User:
- Hospitals
- Cancer Centers
- Others
Malignant Mesothelioma Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Malignant Mesothelioma Therapeutics Market.
Available Customizations:
Global Malignant Mesothelioma Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Malignant Mesothelioma Therapeutics Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others)
- 5.2.2. By Route of Administration (Oral, Parenteral)
- 5.2.3. By End User (Hospitals, Cancer Centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. North America Malignant Mesothelioma Therapeutics Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Route of Administration
- 6.2.3. By End User
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Malignant Mesothelioma Therapeutics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug Type
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By End User
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Malignant Mesothelioma Therapeutics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug Type
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By End User
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Malignant Mesothelioma Therapeutics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug Type
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By End User
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Malignant Mesothelioma Therapeutics Market Outlook
7. Europe Malignant Mesothelioma Therapeutics Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Route of Administration
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Type
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By End User
- 7.3.1.1. Market Size & Forecast
- 7.3.2. United Kingdom Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Type
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By End User
- 7.3.2.1. Market Size & Forecast
- 7.3.3. Italy Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Type
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By End User
- 7.3.3.1. Market Size & Forecast
- 7.3.4. France Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug Type
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By End User
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Malignant Mesothelioma Therapeutics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug Type
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By End User
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Malignant Mesothelioma Therapeutics Market Outlook
8. Asia-Pacific Malignant Mesothelioma Therapeutics Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Route of Administration
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Type
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By End User
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Type
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By End User
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Type
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By End User
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Type
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By End User
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Malignant Mesothelioma Therapeutics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Type
- 8.3.5.2.2. By Route of Administration
- 8.3.5.2.3. By End User
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Malignant Mesothelioma Therapeutics Market Outlook
9. South America Malignant Mesothelioma Therapeutics Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Route of Administration
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Malignant Mesothelioma Therapeutics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Type
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By End User
- 9.3.1.1. Market Size & Forecast
- 9.3.2. Argentina Malignant Mesothelioma Therapeutics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Type
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By End User
- 9.3.2.1. Market Size & Forecast
- 9.3.3. Colombia Malignant Mesothelioma Therapeutics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Type
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By End User
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Brazil Malignant Mesothelioma Therapeutics Market Outlook
10. Middle East and Africa Malignant Mesothelioma Therapeutics Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Route of Administration
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Malignant Mesothelioma Therapeutics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Type
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By End User
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Saudi Arabia Malignant Mesothelioma Therapeutics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Type
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By End User
- 10.3.2.1. Market Size & Forecast
- 10.3.3. UAE Malignant Mesothelioma Therapeutics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Type
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By End User
- 10.3.3.1. Market Size & Forecast
- 10.3.1. South Africa Malignant Mesothelioma Therapeutics Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porter's Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. F. Hoffmann-La Roche Ltd
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Novartis AG
- 14.3. Merck & Co. Inc.
- 14.4. Pfizer Inc.
- 14.5. Eli Lilly and Co.
- 14.6. Sanofi S.A.
- 14.7. AstraZeneca Plc
- 14.8. Bayer AG
- 14.9. Regeneron Pharmaceuticals Inc.
- 14.10. GSK Plc
15. Strategic Recommendations
16. About Us & Disclaimer
